FibroBiologics updates $7.5M ATM stock program
FibroBiologics, Inc. has updated its existing at-the-market stock offering program with H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
FibroBiologics, Inc. has updated its existing at-the-market stock offering program with H.C. Wainwright & Co. Under a new prospectus supplement filed on May 5, 2026, the company may sell shares of common stock for an aggregate offering price of up to $7,500,000 under this ATM facility.
The ATM sales are made pursuant to FibroBiologics’ shelf registration statement on Form S-3, declared effective by the SEC on February 10, 2025, and related prospectus supplements. To date, 71,830 shares have been sold under the Sales Agreement. The company also filed its counsel’s legal opinion and consent covering the validity of the shares issuable under the program.
8-K Event Classification
2 items: 1.01, 9.01
2 items
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
ATM aggregate capacity: $7,500,000
Shares sold to date: 71,830 shares
Shelf registration number: 333-284663
+1 more
4 metrics
ATM aggregate capacity
$7,500,000
Maximum aggregate offering price under updated ATM prospectus supplement
Shares sold to date
71,830 shares
Common stock already sold under the At The Market Offering Agreement
Shelf registration number
333-284663
Form S-3 shelf supporting the ATM offering
Shelf effectiveness date
February 10, 2025
Date Form S-3 registration statement was declared effective by the SEC
Key Terms
At The Market Offering Agreement, shelf registration statement on Form S-3, prospectus supplement, emerging growth company, +1 more
5 terms
At The Market Offering Agreement financial
"entered into that certain At The Market Offering Agreement (the “Sales Agreement”)"
An at-the-market offering agreement is a contract that lets a company sell newly issued shares directly into the open market through a broker, at whatever price the stock is trading at that moment. For investors this matters because it can increase the number of shares available (which may dilute existing ownership) while providing a flexible, often faster way for the company to raise cash without fixing a price, similar to a vendor selling small batches at current market stalls rather than setting a single fixed price.
shelf registration statement on Form S-3 regulatory
"pursuant to the Company’s shelf registration statement on Form S-3 (Registration No. 333-284663)"
A shelf registration statement on Form S-3 is a pre-approved filing with the Securities and Exchange Commission that lets an eligible public company register securities in advance and sell them later in one or more offerings without repeating the full registration process. Think of it like a pre-approved funding line: it gives management the flexibility to raise capital quickly when market conditions are right, a move that can affect share supply, dilution and investor returns, so investors monitor it as a signal of potential financing activity.
prospectus supplement regulatory
"a prospectus supplement which was filed with the SEC on May 1, 2026"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
emerging growth company regulatory
"Emerging growth company Item 1.01 Entry into a Material Definitive Agreement."
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
aggregate offering price financial
"issuable pursuant to the ATM Offering to up to an aggregate offering price of up to $7,500,000"
The aggregate offering price is the total dollar amount that will be raised if all the securities in an offering are sold at the stated offering price, before fees or expenses are taken out. Investors use it to gauge the size of the fundraising and its potential effects—such as how much cash the company will get and how much existing ownership might be reduced—similar to totaling every item’s price in a shopping cart to see the full bill.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did FibroBiologics (FBLG) change in its at-the-market offering?
FibroBiologics increased the capacity of its at-the-market stock offering to an aggregate offering price of $7,500,000. This allows the company to issue and sell additional common shares over time through its Sales Agent under an effective shelf registration.
How is FibroBiologics’ $7.5 million ATM offering structured?
The ATM offering allows FibroBiologics to sell common stock, from time to time, through H.C. Wainwright & Co. for up to $7,500,000 in aggregate. Sales are made under a Form S-3 shelf registration and related prospectus supplements, including the Updated ATM Prospectus Supplement.
What SEC registration supports FibroBiologics’ ATM program?
The ATM program is conducted under FibroBiologics’ shelf registration statement on Form S-3, Registration No. 333-284663. This registration was filed with the SEC on February 3, 2025, and declared effective on February 10, 2025, enabling ongoing issuances.
What role does H.C. Wainwright play in FibroBiologics’ ATM offering?
H.C. Wainwright & Co. acts as the Sales Agent under the At The Market Offering Agreement. It may sell FibroBiologics’ common stock into the market on the company’s behalf, subject to the terms of the Sales Agreement and applicable securities laws.
Why did FibroBiologics file legal opinions with this 8-K?
FibroBiologics filed an opinion and consent from Sichenzia Ross Ference Carmel LLP as Exhibits 5.1 and 23.1. These documents address the validity of the common shares that may be issued under the ATM program and provide the related legal consent.
AI-generated analysis. How Rhea-AI works. Not financial advice.
